Stress oxydatif & Maladie Cardiovasculaire

Nom du produit


Enzyme Immunoassay for the quantitative determination of Malondialdehyd oxidized Low-Density-Lipoprotein (MDA-oxLDL) in human serum and plasma

Cat. noBI-20022
Gamme0 – 10 µg/ml
Sensibilité0.05 µg/ml (STD2 0.6 µg/ml)
Durée d'incubation3.5 hours
Volume échantillon20 µl

Serum, EDTA-, citrate, heparin plasma


Centrifuge freshly collected blood as soon as possible
Store centrifuged samples at -20°C for longer storage.
Samples are stable up to 4 freeze and thaw cycles.
Hemolyzed or lipemic samples may cause erroneous results.

Valeurs de référence

Median = 1.0 μg/ml (n = 70)



Intérêt clinique

Intended use: Research use only.

Oxidatively modified lipoproteins (oxLDLs) play an important role in the progression of atherosclerosis and coronary artery disease. Low-density lipoprotein (LDL), the main carrier of plasma cholesterol, consists of a hydrophobic core and a surface monolayer of polar lipids and Apolipoprotein-B (ApoB). Oxidative stress and the consequent formation of free radicals lead to the peroxidation of ApoB. Malondialdehyde (MDA) has been identified as one of the major lipid peroxidation products of LDL, thus playing an important role in the LDL oxidation. The Biomedica MDA-oxLDL ELISA specifically detects MDA-modified Apo B in human serum and plasma.

Intended applications:

Cardiovascular Disease - atherosclerosis, coronary artery disease, myocardial infarction

Informations utiles

Retour à l'index